ENSG00000215301 |
DDX3X |
central nervous system primitive neuroectodermal neoplasm |
sequence_alteration |
7.522% (34/452) |
1 entry |
ENSG00000215301 |
DDX3X |
colorectal adenocarcinoma |
missense_variant |
2.988% (34/1138) |
3 entries |
ENSG00000215301 |
DDX3X |
medulloblastoma |
missense_variant |
29.17% (7/24) |
1 entry |
ENSG00000215301 |
DDX3X |
central nervous system primitive neuroectodermal neoplasm |
missense_variant |
7.522% (34/452) |
5 entries |
ENSG00000215301 |
DDX3X |
colorectal adenocarcinoma |
stop_gained |
2.988% (34/1138) |
1 entry |
ENSG00000215301 |
DDX3X |
colorectal adenocarcinoma |
sequence_alteration |
2.988% (34/1138) |
3 entries |
ENSG00000215301 |
DDX3X |
prostate adenocarcinoma |
frameshift_variant |
1.231% (18/1462) |
1 entry |
ENSG00000215301 |
DDX3X |
bronchoalveolar adenocarcinoma |
missense_variant |
13.64% (3/22) |
1 entry |
ENSG00000215301 |
DDX3X |
chronic lymphocytic leukemia |
missense_variant |
1.66% (17/1024) |
1 entry |
ENSG00000215301 |
DDX3X |
Pleural Epithelioid Mesothelioma |
missense_variant |
5.063% (8/158) |
2 entries |
ENSG00000215301 |
DDX3X |
small cell lung carcinoma |
missense_variant |
0.9434% (3/318) |
2 entries |
ENSG00000215301 |
DDX3X |
breast ductal adenocarcinoma |
missense_variant |
2.593% (16/617) |
3 entries |
ENSG00000215301 |
DDX3X |
pharyngeal squamous cell carcinoma |
missense_variant |
6.452% (2/31) |
1 entry |
ENSG00000215301 |
DDX3X |
squamous cell lung carcinoma |
missense_variant |
1.05% (8/762) |
1 entry |
ENSG00000215301 |
DDX3X |
prostate adenocarcinoma |
missense_variant |
1.231% (18/1462) |
2 entries |
ENSG00000215301 |
DDX3X |
small cell lung carcinoma |
sequence_alteration |
0.9434% (3/318) |
2 entries |
ENSG00000215301 |
DDX3X |
medulloblastoma |
sequence_alteration |
29.17% (7/24) |
1 entry |
ENSG00000215301 |
DDX3X |
squamous cell lung carcinoma |
sequence_alteration |
1.05% (8/762) |
2 entries |
ENSG00000215301 |
DDX3X |
female breast carcinoma |
missense_variant |
1.124% (3/267) |
2 entries |
ENSG00000215301 |
DDX3X |
T-cell acute lymphoblastic leukemia |
missense_variant |
1.312% (5/381) |
2 entries |
ENSG00000215301 |
DDX3X |
skin melanoma |
missense_variant |
2.068% (20/967) |
3 entries |
ENSG00000215301 |
DDX3X |
HER2 Positive Breast Carcinoma |
missense_variant |
7.018% (8/114) |
2 entries |
ENSG00000215301 |
DDX3X |
diffuse large B-cell lymphoma |
missense_variant |
2.288% (7/306) |
3 entries |
ENSG00000215301 |
DDX3X |
prostate carcinoma |
sequence_alteration |
0.4695% (2/426) |
1 entry |
ENSG00000215301 |
DDX3X |
melanoma |
missense_variant |
2.941% (3/102) |
1 entry |
ENSG00000215301 |
DDX3X |
prostate adenocarcinoma |
sequence_alteration |
1.231% (18/1462) |
2 entries |
ENSG00000215301 |
DDX3X |
chronic lymphocytic leukemia |
sequence_alteration |
1.66% (17/1024) |
1 entry |
ENSG00000215301 |
DDX3X |
head and neck squamous cell carcinoma |
frameshift_variant |
0.8043% (6/746) |
1 entry |
ENSG00000215301 |
DDX3X |
malignant epithelioid mesothelioma |
missense_variant |
16.67% (2/12) |
1 entry |
ENSG00000215301 |
DDX3X |
Pleural Epithelioid Mesothelioma |
stop_gained |
5.063% (8/158) |
1 entry |
ENSG00000215301 |
DDX3X |
chronic lymphocytic leukemia |
frameshift_variant |
1.66% (17/1024) |
1 entry |
ENSG00000215301 |
DDX3X |
colorectal adenocarcinoma |
frameshift_variant |
2.988% (34/1138) |
1 entry |
ENSG00000215301 |
DDX3X |
nasopharyngeal squamous cell carcinoma |
sequence_alteration |
1.796% (3/167) |
1 entry |
ENSG00000215301 |
DDX3X |
bladder transitional cell carcinoma |
missense_variant |
2.92% (4/137) |
2 entries |
ENSG00000215301 |
DDX3X |
ovarian teratoma |
missense_variant |
5.556% (3/54) |
1 entry |
ENSG00000215301 |
DDX3X |
head and neck squamous cell carcinoma |
sequence_alteration |
0.8043% (6/746) |
1 entry |
ENSG00000215301 |
DDX3X |
esophageal squamous cell carcinoma |
sequence_alteration |
1.625% (11/677) |
2 entries |
ENSG00000215301 |
DDX3X |
breast carcinoma |
missense_variant |
0.7796% (11/1411) |
1 entry |
ENSG00000215301 |
DDX3X |
gastric intestinal type adenocarcinoma |
missense_variant |
2.353% (2/85) |
2 entries |
ENSG00000215301 |
DDX3X |
esophageal squamous cell carcinoma |
frameshift_variant |
1.625% (11/677) |
3 entries |
ENSG00000215301 |
DDX3X |
pancreatic ductal adenocarcinoma |
missense_variant |
1.589% (20/1259) |
2 entries |
ENSG00000215301 |
DDX3X |
colon adenocarcinoma |
sequence_alteration |
0.9472% (7/739) |
2 entries |
ENSG00000215301 |
DDX3X |
colon adenocarcinoma |
missense_variant |
0.9472% (7/739) |
5 entries |
ENSG00000215301 |
DDX3X |
Pleural Epithelioid Mesothelioma |
sequence_alteration |
5.063% (8/158) |
1 entry |
ENSG00000215301 |
DDX3X |
hepatocellular carcinoma |
sequence_alteration |
0.6652% (6/902) |
1 entry |
ENSG00000215301 |
DDX3X |
head and neck squamous cell carcinoma |
missense_variant |
0.8043% (6/746) |
2 entries |
ENSG00000215301 |
DDX3X |
esophageal squamous cell carcinoma |
missense_variant |
1.625% (11/677) |
2 entries |
ENSG00000215301 |
DDX3X |
nasopharyngeal squamous cell carcinoma |
missense_variant |
1.796% (3/167) |
1 entry |
ENSG00000215301 |
DDX3X |
lung adenocarcinoma |
missense_variant |
1.376% (16/1163) |
6 entries |
ENSG00000215301 |
DDX3X |
lung adenocarcinoma |
sequence_alteration |
1.376% (16/1163) |
3 entries |
ENSG00000215301 |
DDX3X |
bronchoalveolar adenocarcinoma |
sequence_alteration |
13.64% (3/22) |
1 entry |
ENSG00000215301 |
DDX3X |
acute lymphoblastic leukemia |
missense_variant |
0.6231% (2/321) |
2 entries |
ENSG00000215301 |
DDX3X |
chronic lymphocytic leukemia |
stop_gained |
1.66% (17/1024) |
1 entry |
ENSG00000215301 |
DDX3X |
hairy cell leukemia |
missense_variant |
4.762% (1/21) |
1 entry |
ENSG00000215301 |
DDX3X |
bladder transitional cell carcinoma |
stop_gained |
2.92% (4/137) |
1 entry |
ENSG00000215301 |
DDX3X |
malignant epithelioid mesothelioma |
sequence_alteration |
16.67% (2/12) |
1 entry |
ENSG00000215301 |
DDX3X |
papillary thyroid carcinoma |
missense_variant |
0.2532% (1/395) |
1 entry |
ENSG00000215301 |
DDX3X |
Pleural Biphasic Mesothelioma |
missense_variant |
1.449% (1/69) |
1 entry |
ENSG00000215301 |
DDX3X |
T-cell acute lymphoblastic leukemia |
sequence_alteration |
1.312% (5/381) |
1 entry |
ENSG00000215301 |
DDX3X |
adenosquamous lung carcinoma |
missense_variant |
9.091% (1/11) |
1 entry |
ENSG00000215301 |
DDX3X |
large cell medulloblastoma |
missense_variant |
15.79% (3/19) |
1 entry |
ENSG00000215301 |
DDX3X |
lung adenocarcinoma |
frameshift_variant |
1.376% (16/1163) |
1 entry |
ENSG00000215301 |
DDX3X |
cecum adenocarcinoma |
stop_gained |
1.587% (2/126) |
1 entry |
ENSG00000215301 |
DDX3X |
breast ductal adenocarcinoma |
stop_gained |
2.593% (16/617) |
2 entries |
ENSG00000215301 |
DDX3X |
laryngeal squamous cell carcinoma |
stop_lost |
3.846% (1/26) |
1 entry |
ENSG00000215301 |
DDX3X |
laryngeal squamous cell carcinoma |
sequence_alteration |
3.846% (1/26) |
1 entry |
ENSG00000215301 |
DDX3X |
squamous cell lung carcinoma |
stop_gained |
1.05% (8/762) |
1 entry |
ENSG00000215301 |
DDX3X |
brain glioblastoma |
sequence_alteration |
0.2157% (2/927) |
1 entry |
ENSG00000215301 |
DDX3X |
malignant epithelioid mesothelioma |
frameshift_variant |
16.67% (2/12) |
1 entry |
ENSG00000215301 |
DDX3X |
bile duct adenocarcinoma |
missense_variant |
0.5291% (1/189) |
1 entry |
ENSG00000215301 |
DDX3X |
small cell lung carcinoma |
frameshift_variant |
0.9434% (3/318) |
1 entry |
ENSG00000215301 |
DDX3X |
skin melanoma |
frameshift_variant |
2.068% (20/967) |
1 entry |
ENSG00000215301 |
DDX3X |
bladder transitional cell carcinoma |
sequence_alteration |
2.92% (4/137) |
1 entry |
ENSG00000215301 |
DDX3X |
ovarian serous adenocarcinoma |
missense_variant |
0.1486% (1/673) |
1 entry |
ENSG00000215301 |
DDX3X |
Endometrial Clear Cell Adenocarcinoma |
missense_variant |
8.333% (1/12) |
1 entry |
ENSG00000215301 |
DDX3X |
oral squamous cell carcinoma |
sequence_alteration |
0.4854% (1/206) |
1 entry |
ENSG00000215301 |
DDX3X |
T-cell acute lymphoblastic leukemia |
frameshift_variant |
1.312% (5/381) |
1 entry |
ENSG00000215301 |
DDX3X |
pharyngeal squamous cell carcinoma |
stop_gained |
6.452% (2/31) |
1 entry |
ENSG00000215301 |
DDX3X |
lung adenocarcinoma |
stop_gained |
1.376% (16/1163) |
1 entry |
ENSG00000215301 |
DDX3X |
melanoma |
frameshift_variant |
2.941% (3/102) |
1 entry |
ENSG00000215301 |
DDX3X |
bile duct adenocarcinoma |
sequence_alteration |
0.5291% (1/189) |
1 entry |
ENSG00000215301 |
DDX3X |
basal cell carcinoma |
missense_variant |
1.724% (1/58) |
1 entry |
ENSG00000215301 |
DDX3X |
clear cell renal carcinoma |
stop_gained |
0.3098% (4/1291) |
1 entry |
ENSG00000215301 |
DDX3X |
melanoma |
sequence_alteration |
2.941% (3/102) |
1 entry |